Early changes in blood-based joint tissue destruction biomarkers are predictive of response to tocilizumab in the LITHE study
Arthritis Research & Therapy (2016) 18:13 DOI: 10.1186/s13075-015-0913-x
One of the major challenges of RA treatment is choosing the correct treatment and dose for the individual patient, as treatment response can be heterogeneous. To help select the appropriate treatment, there is a need for effective and non-invasive ways to monitor disease activity and progression. In the LITHE study, Bay-Jensen et al. investigate whether early biomarker measurements could predict early joint protection response to TCZ. The biomarkers (CRPM, VICM, C1M, C2M, C3M, and CTX-I/OC [bone...